NRX Pharmaceuticals (NRXP) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Seer (SEER) has outperformed NRX Pharmaceuticals (NRXP) over the past year, losing 0.5% versus a loss of 21.0%. Over five years, SEER leads with a -93.3% price change compared with -97.2% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($125.1 million vs $120.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | SEER |
|---|---|---|
| Share price | $2.89 | $2.17 |
| Market cap | $125.12M | $120.16M |
| 1-day change | -0.34% | -1.81% |
| YTD return | +7.01% | +20.77% |
| 1-year return | -20.98% | -0.45% |
| 5-year return | -97.17% | -93.30% |
| EPS (TTM) | $-0.58 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.06 | $2.41 |
| 52-week low | $1.62 | $1.55 |
| Distance from 52-week high | -42.83% | -9.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1232.18% | +84.33% |
| Average volume | 867.50K | 481.54K |
| Shares outstanding | 43.30M | 55.37M |
| Employees | 29 | 124 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEER has outperformed NRXP by 20.5 percentage points over the past year.
- The two companies sit in different sectors: NRX Pharmaceuticals in Health Care and Seer in Industrials.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Industrials · Biotechnology: Laboratory Analytical Instruments · 124 employees
NRXP vs SEER FAQ
Which is bigger, NRX Pharmaceuticals or Seer?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $125.12M compared with $120.16M for Seer (SEER).
Which stock has performed better over the past year, NRXP or SEER?
SEER returned -0.45% over the past 12 months, compared with -20.98% for NRXP (price return, excluding dividends). Past performance does not predict future results.
Are NRX Pharmaceuticals and Seer in the same industry?
No. NRX Pharmaceuticals is in the Health Care sector, while Seer is in Industrials.